You are here: Industry Insights > Forxiga

News List

Forxiga Approved in EU to Treat Chronic Kidney Disease americanpharmaceuticalreview
August 10, 2021
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease pharmatimes
August 09, 2021
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the European Commission for the treatment of chronic kidney disease (CKD) in the European Union (EU).
Four medicines accepted for use by NHS Scotland pharmatimes
April 13, 2021
The Scottish Medicines Consortium (SMC) has approved NHS funding for four new medicines, including treatments for multiple myeloma and severe migraine in its April 2020 decisions.
China approves AstraZeneca’s Forxiga for heart failure pharmaceutical-technology
February 07, 2021
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes.
US priority review for Forxiga in chronic kidney disease pharmatimes
January 07, 2021
The US Food and Drug Administration (FDA) has granted AstraZeneca’s Forxiga (dapagliflozin) a priority review for the treatment of new or worsening chronic kidney disease (CKD).
Forxiga Approved in Japan for Chronic Heart Failure americanpharmaceuticalreview
December 16, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving standard of care.
AstraZeneca’s heart failure treatment Forxiga gets approval in Japan pharmaceutical-technology
December 02, 2020
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Forxiga (dapagliflozin) for treating patients with chronic heart failure (HF) who are receiving standard of care in the country.
Forxiga Approved in the EU for Heart Failure americanpharmaceuticalreview
November 13, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes (T2D).
AZ’s Forxiga wins EU approval for heart failure pharmatimes
November 06, 2020
AstraZeneca’s Forxiga (dapagliflozin) has been approved in the EU for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF).
CHMP recommends AstraZeneca’s Forxiga for approval in EU pharmaceutical-technology
October 21, 2020
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended AstraZeneca’s Forxiga (dapagliflozin) for an indication extension of its marketing authorisation in the European Union (EU).

Previous page 1 2 Next page